PMID- 32419364
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 14
DP  - 2020 Jul
TI  - Clinical and immunological features of platelet transfusion refractoriness in 
      young patients with de novo acute myeloid leukemia.
PG  - 4941-4948
LID - 10.1002/cam4.3140 [doi]
AB  - Platelet transfusion is important in the prevention and treatment of bleeding in 
      patients with acute myeloid leukemia (AML) after receiving intensive 
      chemotherapy. However, platelet transfusion refractoriness (PTR) is an 
      intractable clinical issue occurred in these patients. And its clinical and 
      immunological features remain largely unknown. The potential causes and clinical 
      features of PTR were retrospectively analyzed in 560 patients who were diagnosed 
      as de novo AML in Tongji Hospital from June 2012 through June 2018. A 
      high-throughput antibody screening for the detection of human leukocyte antigen 
      (HLA) and its serotypes was performed in 133 newly diagnosed AML patients. PTR 
      occurred in 11.8% of the de novo AML patients. The median age for patients with 
      PTR was 46 years (range, 15-70). It frequently manifested in female patients and 
      in patients with splenomegaly, M4 subtype, c-Kit gene mutation, and 
      rearrangements of RUNX1-RUNX1T1 or CBFB-MYH11, commonly referred to as core 
      binding factor AML (CBF-AML). Notably, CBF-AML was independently associated with 
      the occurrence of PTR. PTR predominantly developed in patients who had CBF-AML 
      (P < .001) and in patients who further had better minimal residual disease (MRD) 
      reduction (>/=3-log) before the second consolidation chemotherapy (P = .007). HLA-I 
      antibodies were detected in the serum of 9.0% of AML patients and markedly 
      enriched in patients with PTR (P < .001) and in patients with CBF-AML (P = .018). 
      HLA-B was the most frequently identified serum epitope in PTR patients. Patients 
      with CBF-AML had higher tendency to develop HLA-I antibodies and PTR, which 
      depicted novel features of PTR in AML and might provide insights into its 
      efficient managements.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Hu, Xuelian
AU  - Hu X
AUID- ORCID: 0000-0002-4792-728X
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Cai, Haodong
AU  - Cai H
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Zheng, Lu
AU  - Zheng L
AD  - Lishui City People's Hospital, Zhejiang, China.
FAU - Luo, Yi
AU  - Luo Y
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Zhou, Jing
AU  - Zhou J
AUID- ORCID: 0000-0002-0373-6924
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Hui, Yan
AU  - Hui Y
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Dai, Zhenyu
AU  - Dai Z
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Lin, Haolong
AU  - Lin H
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Li, Dengju
AU  - Li D
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Xiao, Yi
AU  - Xiao Y
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Huang, Liang
AU  - Huang L
AUID- ORCID: 0000-0002-8370-3232
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Zhou, Jianfeng
AU  - Zhou J
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200518
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Transfusion/*methods
MH  - Risk Factors
PMC - PMC7367618
OTO - NOTNLM
OT  - core binding factor acute myeloid leukemia
OT  - human leukocyte antigen
OT  - platelet transfusion refractoriness
OT  - risk factor
COIS- The authors declare that they have no conflict of interests.
EDAT- 2020/05/19 06:00
MHDA- 2021/05/14 06:00
PMCR- 2020/05/18
CRDT- 2020/05/19 06:00
PHST- 2019/12/21 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/18 00:00 [pmc-release]
AID - CAM43140 [pii]
AID - 10.1002/cam4.3140 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Jul;9(14):4941-4948. doi: 10.1002/cam4.3140. Epub 2020 May 18.